title: [Prophylactic antiretroviral therapy after sexual exposure to HIV: 93 cases].
abstract: METHODS
  We studied prospectively the feasibility of post exposure prophylaxis against HIV in 93 subjects consulting after sexual exposure at STD Center of Hopital Saint-Louis. Among the 93 subjects, 76 were men (45 homosexual) and 17 women.
  
  
  RESULTS
  Delay to consultation was 38 h. Among sexual exposure 90 p. 100 were anal or vaginal intercourse and 10 p. 100 oral intercourse. Fifty percent were unprotected. Seventy-five percent of source subject HIV status was unknown, but controlled negative in 14 p. 100 of cases. Three subjects were infected initially. Seventy-two subjects were treated, with triple regimen, for 30 days without severe adverse event. Twenty-five percent were lost to follow up before the end of treatment, only 54 controlled their serology after the end of treatment (after 1 month: 70 p. 100, after 2 months: 51 p. 100 and after 4-6 months: 13 p. 100).
  
  
  CONCLUSIONS
  This study underlines the difficulty in obtaining clinical and serological control after post exposure prophylaxis, even in a STD Department involved in prevention and counseling.
authors.affiliation: Centre Clinique et Biologique des MST, Hôpital Saint-Louis, 42, rue Bichat, Pavillon Lailler, 75475 Paris Cedex 10, France.
authors.forename: F J
authors.initials: FJ
authors.lastname: Timsit
authors.forename: A
authors.initials: A
authors.lastname: Maillard
authors.forename: E
authors.initials: E
authors.lastname: Spindler
authors.forename: Y
authors.initials: Y
authors.lastname: Taquin
authors.forename: F
authors.initials: F
authors.lastname: Deniaud
authors.forename: F
authors.initials: F
authors.lastname: Ferchal
authors.forename: P
authors.initials: P
authors.lastname: Morel
authors.forename: M
authors.initials: M
authors.lastname: Janier
mesh_terms: D015492:AIDS Serodiagnosis; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005240:Feasibility Studies; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission*; D006801:Humans; D019469:Indinavir / Q000627:therapeutic use*; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D019888:Nelfinavir / Q000627:therapeutic use*; D010297:Paris / Q000453:epidemiology; D011446:Prospective Studies; D012725:Sexual Behavior / Q000706:statistics & numerical data; D013997:Time Factors; D016896:Treatment Outcome; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir; D019888:Nelfinavir